These pivotal studies reveal new ways to optimize commonly used chemotherapy, hormone therapies, and newer targeted drugs, and answer critical questions about the comparative effectiveness of two common treatment regimens for advanced colorectal cancer. All four trials were supported, at least in part, with federal funding through the
"Today's results answer critical questions faced by people with cancer and their doctors every day. There is no doubt that patients will live longer and better because of these studies," said
The Plenary studies are:
Adjuvant exemestane is more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer: Post-surgery (adjuvant) exemestane is more effective at preventing breast cancer recurrences than tamoxifen when given with ovarian function suppression in young women with hormone receptor-positive, early breast cancer, reducing the relative risk of developing a recurrent cancer by 28 percent.
Addition of docetaxel to initial hormone therapy substantially improves survival in men with metastatic, hormone-sensitive prostate cancer: The findings suggest inclusion of docetaxel in first-line therapies for men with advanced disease who are healthy enough for chemotherapy, especially those with extensive disease spread.
First-line bevacizumab plus chemotherapy and cetuximab plus chemotherapy provide similar survival benefit for patients with metastatic colorectal cancer: Large U.S.-funded head-to-head comparison trial answers a long-standing question about the relative effectiveness of four common regimens, offering patients and providers new reassurance as they face treatment decisions.
Adding lapatinib to adjuvant trastuzumab does not improve outcomes for women with early-stage HER2-positive breast cancer: Results from the phase III ALTTO study indicate that post-surgery treatment with the two anti-HER2 drugs does not improve disease-free survival compared to standard treatment with trastuzumab alone.
Keywords for this news article include: Antineoplastic Monoclonal Antibodies, Biotechnology, Drugs, Surgery, Hormones, Trastuzumab, Chemotherapy, HER2 Inhibitors, Medical Devices, Gastroenterology, Tyrosine Kinase Inhibitors, Clinical Trials and Studies,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- GE Healthcare Bringing Jobs to Massachusetts
- Hispanic NASCAR Driver Ready to Make History
- Faith Groups Divest From Fossil Fuels
- James Foley Beheading Video Is Real Thing: White House
- James Foley Killer Could Be ID'd Via Social Media, Voice Recognition
- Apple Stock Bounces Back Big Time
- Bank of America Agrees to Pay Record $16.65 Billion
- Stocks Moving Higher Again for 4th Day
- Entrepreneur Contest Announced in Idaho
- U.S. Existing Home Sales Rise 4th Month Straight